Trial Profile
A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Diclofenac potassium (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Assertio Therapeutics; Depomed
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
- 07 Aug 2020 Results published in the Headache.
- 10 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.